EUK 189
Alternative Names: EUK-189; Synthetic catalytic scavengerLatest Information Update: 09 Jan 2009
At a glance
- Originator Proteome Systems
- Developer Tyrian Diagnostics
- Class Organometallic compounds; Salicylates; Small molecules
- Mechanism of Action Free radical scavengers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cognition disorders; Radiation-induced skin damage
Most Recent Events
- 09 Jan 2009 Discontinued - Phase-I for Radiation-induced skin damage in USA (Topical)
- 10 May 2007 Minerva Healthcare Inc. granted an option to license EUK 189 and other topical Eukarion compounds
- 17 Nov 2006 Phase-I clinical trials in Radiation-induced skin damage in USA (Topical)